Plasma protein biomarkers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: Results from CALGB 80405 (Alliance)
- Citation:
- Clin Cancer Res vol 28 (13) 2779-88
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Bristol-Myers, Genentech, Pfizer, and Sanofi
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233290, UG1CA233337, UG1CA233373, UG1CA189862, U10CA180820 (ECOG-ACRIN), UG1CA180830, U10CA180888 (SWOG)
- Corr. Author:
- Authors:
- Andrew B. Nixon Alexander B. Sibley Yingmiao Liu Ace J. Hatch Chen Jiang Flora Mulkey Mark D. Starr John C. Brady Donna Niedzwiecki Alan P. Venook Luis Baez-Diaz Heinz-Josef Lenz Bert H. O'Neil Federico Innocenti Jeffrey A. Meyerhardt Eileen M O'Reilly Kouros Owzar Herbert I. Hurwitz
- Networks:
- CA011, CA136, LAPS-IN007, LAPS-MA036, LAPS-NC007, LAPS-NC010, LAPS-NY016
- Study
- CALGB-80405
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: